CVS Health Corp will need a revision to its business model in order to survive an ever-changing retail/pharmacy environment. However, with a P/E of 10x, debt-to-equity of less than 1x, growing cash flow, and dividend yield of 4.3%, the stock seems quite undervalued. Perhaps activist investors will soon step in, but if history repeats, there may be a nice bounce ahead as the price consolidates in the 50S and low 60s. Thus, near its current price of $61, CVS is in a personal buy zone.
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.